Respiratory Conditions

NHS prescribing intelligence on inhalers, spacers, drugs and other devices used in asthma and COPD

Treatment of respiratory conditions represents a significant part of UK community prescribing, by spend and by number of prescription items. Nearly 12% of spend in England in 2017 and 6.5% of prescription items related to the respiratory system (BNF chapter 3). Two of the top ten BNF sections when ranked by net ingredient cost are therapies for respiratory conditions; corticosteroids is the second highest section in terms of spend and bronchodilators is the seventh highest.


Additional resources on prescribing for respiratory conditions

Please see below for some of GPrX's content relating to respiratory conditions

Further Resources:

Other industry sectors Free useful downloads